IHH Healthcare Expands Leo Cancer Care Partnership to Deploy Upright Radiotherapy Across Asia

Leo Cancer Care and IHH Healthcare have deepened their partnership to bring a new generation of cancer treatment equipment to hospitals across Asia. The collaboration, announced in late September, marks IHH's commitment to deploying upright radiotherapy systems—a technology that fundamentally changes how radiation therapy is delivered to patients.

The core innovation is deceptively simple: instead of rotating the radiation beam around a patient, Leo Cancer Care's systems rotate the patient instead. This architectural shift has profound consequences. Conventional radiotherapy equipment is massive, expensive, and demands significant infrastructure investment. By inverting the engineering problem, upright systems shrink dramatically in size and cost, making advanced cancer treatment accessible to hospitals that previously couldn't justify the expense or space requirements.

IHH Healthcare operates 140 healthcare facilities across ten countries—Malaysia, Singapore, Turkey, India, Greater China, and others—employing 70,000 people. The health system manages everything from primary care clinics to quaternary hospitals under brands including Acibadem, Gleneagles, Fortis, and Mount Elizabeth. This scale matters because it means the partnership will touch thousands of patients across a region where cancer care infrastructure remains unevenly distributed.

The expanded deal covers two distinct technologies. The first is Grace, Leo Cancer Care's upright linear accelerator—the workhorse machine that delivers photon therapy, the most common form of radiotherapy. Grace remains in research phase and is not yet commercially available, but IHH has committed to introducing it across its network once regulatory clearance arrives. The second is Marie, a compact upright proton therapy system. Proton therapy has long been recognized as superior for certain cancers because protons deposit their destructive energy precisely at the tumor site, sparing surrounding healthy tissue. But conventional proton systems are room-sized, cost hundreds of millions of dollars, and require specialized facilities. Marie's upright design promises to change that calculus entirely.

What distinguishes this partnership from a simple equipment purchase is that IHH has become an equity investor in Leo Cancer Care itself. This signals confidence beyond the immediate transaction—IHH is betting on the company's long-term viability and the technology's eventual dominance in the market. Elizabeth Han, IHH's Group Head of Innovation and Transformation, framed the move as central to the health system's philosophy: technology and innovation as tools for better patient outcomes. Stephen Towe, Leo Cancer Care's CEO, emphasized that the partnership reflects a different philosophy than the industry norm—simplifying radiotherapy rather than complicating it, reducing costs rather than inflating them.

Proton therapy adoption has been constrained by exactly these factors: size, cost, and infrastructure demands. A conventional proton center requires a building the size of a small hospital and a capital investment that only the wealthiest institutions can absorb. By rotating the patient instead of the beam, Marie reduces the footprint and the price tag, theoretically bringing proton therapy within reach for regional hospitals and middle-income countries. For a health system operating across Asia, where cancer incidence is rising and healthcare resources are stretched, this matters enormously.

IHH's move positions it as the first major Asian health system to commit seriously to upright radiotherapy at scale. The partnership is not yet delivering patients to treatment—Grace is still in research, and Marie exists as a prototype. But the announcement signals where the industry is headed and which institutions are willing to lead. For patients in IHH's network, the practical benefit remains years away. For the broader conversation about how to democratize advanced cancer care, the partnership is already reshaping the terms.